Key Points IBM struck a deal to add Confluent to its rapidly expanding cloud portfolio. The data-streaming platform could accelerate IBM's AI initiatives. 10 stocks we like better than International Business Machines › IBM (NYSE: IBM) wants to be an artificial intelligence (AI) powerhouse. The tech giant is scooping up data-streaming dynamo Confluent (NASDAQ: CFLT) to add to its growing collection of AI-enablers. Under the terms of the deal announced Monday, IBM will purchase Confluent for $11 bil ...

Adding a foundational piece to its cloud and AI strategies.International Business Machines (IBM +0.41%) is taking a distinctly different approach to artificial intelligence compared to its major tech peers. You won't see IBM plowing untold billions into massive AI data centers. In fact, IBM CEO Arvind Krishna stated in a recent interview with The Verge that he sees little chance of the trillions of dollars in capital spending on AI data centers yielding acceptable returns.Krishna is still excited about AI, ...

Core Insights - Confluent is a data infrastructure company specializing in real-time data streaming, allowing businesses to build applications that respond to data in real-time [1] - IBM has announced its acquisition of Confluent for $11 billion in cash, valued at $31.00 per share, which is slightly above the current stock price [2] - The acquisition is part of IBM's strategy to enhance its data and automation offerings amid the growing trend of cloud migration and AI adoption [2] Stock Performance - Despite a downgrade from Piper Sandler from Overweight to Neutral, Confluent's stock has increased by 28.54%, with a change of $6.61 [3] - The stock has fluctuated between $29.70 and $29.86, with a market capitalization of approximately $10.41 billion [3] - High trading volume of 66.97 million shares indicates strong investor interest [3] Investigation - Halper Sadeh LLC is investigating the fairness of the proposed sale to IBM, focusing on the best interests of Confluent shareholders and the board's fiduciary duties [4]

Group 1 - The core focus of the news is the investigation by Monteverde & Associates PC into the proposed sale of Confluent, Inc. to IBM, with a specific emphasis on whether the $31.00 per share offer is fair for shareholders [1] - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report, highlighting its successful track record in recovering millions for shareholders [1] - The firm operates from the Empire State Building in New York City and emphasizes its national presence in class action securities litigation [2][3] Group 2 - The proposed transaction involves Confluent shareholders receiving $31.00 per share of common stock, raising questions about the fairness of the deal [1] - The firm encourages shareholders with concerns to reach out for additional information, indicating a proactive approach to shareholder rights [3] - Monteverde & Associates PC has a history of litigating and recovering funds for shareholders, showcasing its expertise in this area [2][4]

IBM announced on Monday it is acquiring Confluent for $11 billion, sending shares of the data streaming platform up about 29% in morning trading. The deal is one of the largest in recent memory for IBM, The Wall Street Journal reported. The company is paying $31 a share for Confluent in an all-cash deal. Confluent will continue to operate as a distinct brand and business within IBM after the close of the deal (which is subject to regulatory approval). "Data is at the heart of what companies need to do to ha ...

Core Viewpoint - IBM is acquiring Confluent for $31 per share in cash, which is expected to enhance IBM's capabilities in artificial intelligence and data management [3][4]. Group 1: Acquisition Details - IBM announced a definitive agreement to acquire all outstanding stock of Confluent for $31 cash per share [3]. - Confluent specializes in preparing data for AI, which will provide IBM with a smart data platform tailored for enterprise IT [3]. - Confluent's total addressable market has doubled in the last four years, reaching approximately $100 billion [3]. Group 2: Financial Implications - The acquisition price represents a premium of about 6.7 times Confluent's trailing sales, compared to IBM's own price-to-sales ratio of 4.5x [6]. - Analysts project IBM's earnings growth at 7% over the next five years, while Confluent is expected to grow at 24% [7]. - Confluent's current revenue of $1.1 billion is relatively small compared to IBM's total revenue of $65.4 billion, raising concerns about its impact on IBM's stock valuation [8].

Welcome to Market Catalysts. I'm Julie Hyman. Here is what we're watching today.First up, IBM will buy Confluent for $9.3% billion. We'll be speaking with the CEO of Confluent to discuss. Plus, the bidding war for Warner Brothers heats up as Paramount makes a hostile bid for the company.and we'll count down to the December FOMC meeting as the Federal Reserve prepares to issue a rate decision. Let's take a look at the major averages. It is already a busy week.It's going to be a busier week as we get that dec ...

Key Takeaways Shares of Confluent (CFLT) surged Monday morning after IBM (IBM) announced a deal to acquire the software maker for $31 per share, valuing Confluent at $11 billion. Confluent's software helps companies manage and organize large amounts of data, an in-demand service as many companies are looking to manage massive data sets that are used in the training and running of artificial intelligence models. IBM said that Confluent "excels at preparing data for AI, keeping it clean and connected across s ...

Group 1 - U.S. stocks experienced a decline, with the Dow Jones falling over 200 points on Monday [1] - Paramount Skydance Corporation launched an all-cash tender offer to acquire Warner Bros. Discovery, Inc. for $30 per share, valuing the company at $108.4 billion [1] - Paramount aims to create a scaled Hollywood leader by merging with Warner Bros. [1] Group 2 - Paramount Skydance shares increased by 9.8% to $14.68 on Monday [2] - Other notable stocks that gained include Wave Life Sciences Ltd., which rose 129.1% to $17.16 after positive interim Phase 1 data for its obesity drug [4] - Structure Therapeutics Inc. saw a gain of 100.5% to $69.30 following the announcement of topline data from its clinical program for obesity treatment [4] Group 3 - Fulcrum Therapeutics, Inc. shares rose 62.3% to $14.44 after reporting initial results from its Phase 1b trial for sickle cell disease [4] - Kymera Therapeutics, Inc. gained 51.2% to $100.75 after reporting successful trial results for its KT-621 drug [4] - Confluent, Inc. shares increased by 29.2% to $29.89 after IBM agreed to acquire the company for $31 per share [4]

MILWAUKEE, Dec. 8, 2025 /PRNewswire/ -- The Ademi Firm is investigating Confluent (NASDAQ: CFLT) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with IBM. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.  There is no cost or obligation to you. In the transaction, Confluent shareholders will receive $31 per share in cash, representing an enterprise value ...